Literature DB >> 16310759

Practical considerations in PTH testing.

Jean-Claude Souberbielle1, Gérard Friedlander, Catherine Cormier.   

Abstract

New knowledge concerning PTH biology have accumulated during the past few years. The finding that the so-called "intact" PTH assays measure a "non-1-84" PTH fragment in addition to full-length PTH has led to the development of new assays. These new assays, which were initially thought to measure 1-84 PTH only, have been shown to recognize also another PTH species called "amino-PTH". As the various names given to the different assay methods are highly confusing, there is a need for a simplified nomenclature. A simple way would be to identify the older "intact" PTH assays as second-generation assays and the new assays (Whole, CAP, BioIntact) as third-generation assays. Although of considerable potential interest for the comprehension of PTH physiology, the third-generation PTH assays have not yet proved to be superior to the second-generation assays in clinical practice. There is thus currently no recommendation to switch from the second-generation to the third-generation assays in clinical practice, or to use a ratio derived from the concommitent measurement of PTH with both assay-generation. Because second- and third-generation PTH assays are usually highly correlated, significant differences in the clinical information provided by these methods are unlikely. However, our opinion is that more definitive bone biopsy studies in dialyzed patients selected according to their bone- and calcium-related treatment are still needed to reach a consensus. Finally, we have proposed that PTH reference values should be established in healthy subjects with a normal vitamin D status. This supposes that 25OHD is measured in the reference population beforehand, and that the subjects with vitamin D insufficiency are eliminated from the reference group. Although more complicated than the usual way to establish normative data, we have shown that it decreases the upper limit of normal by 25-35%, enhancing thus the diagnostic sensitivity for hyperparathyroidism without a decrease in specificity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16310759     DOI: 10.1016/j.cca.2005.10.010

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  5 in total

1.  Comparison of two commercially available ELISAs for circulating sclerostin.

Authors:  A G Costa; S Cremers; E Dworakowski; M Lazaretti-Castro; J P Bilezikian
Journal:  Osteoporos Int       Date:  2014-02-22       Impact factor: 4.507

2.  Establishment of a normal reference value of parathyroid hormone in a large healthy Chinese population and evaluation of its relation to bone turnover and bone mineral density.

Authors:  M Li; F Lv; Z Zhang; W Deng; Y Li; Z Deng; Y Jiang; O Wang; X Xing; L Xu; W Xia
Journal:  Osteoporos Int       Date:  2016-01-05       Impact factor: 4.507

Review 3.  Biochemical markers for assessment of calcium economy and bone metabolism: application in clinical trials from pharmaceutical agents to nutritional products.

Authors:  Jean-Philippe Bonjour; Wendy Kohrt; Régis Levasseur; Michelle Warren; Susan Whiting; Marius Kraenzlin
Journal:  Nutr Res Rev       Date:  2014-11-14       Impact factor: 7.800

4.  Do current screening recommendations allow for early detection of lithium-induced hyperparathyroidism in patients with bipolar disorder?

Authors:  Michael Berger; Michael Riedel; Nora Tomova; Michael Obermeier; Florian Seemüller; Sandra Dittmann; Hans-Jürgen Moeller; Emanuel Severus
Journal:  Int J Bipolar Disord       Date:  2013-06-14

Review 5.  Parathyroid Hormone Measurement in Chronic Kidney Disease: From Basics to Clinical Implications.

Authors:  Kittrawee Kritmetapak; Chatlert Pongchaiyakul
Journal:  Int J Nephrol       Date:  2019-09-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.